VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that, further to the Company’s press release dated April 21, 2021, the Company’s team of scientists at its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has received positive results and believes that replication of its proprietary recombinant production system (the “Production System”), currently proven and utilized for the production of psilocybin, will result in successful production of API-Grade N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)).
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
Globe Newswire -
Thu Feb 10, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Berskshire%20Hathaway%20Warren%20Buffett%20image%20by%20QubixStudio%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
/Berkshire%20Hathaway%20Inc_%20logo%20on%20phone-by%20FelloeNeko%20via%20Shutterstock.jpg)